At VenomAid we are on a mission to enable best-in-class snakebite care and reduce the global burden of snakebites. By combining state-of-the-art antibody discovery, venomics insights, and affordable diagnostic technologies, we are developing the necessary tools to empower clinicians dealing with snakebite. With a heartfelt vision of a safer, more resilient world, we're tirelessly working to elevate snakebite care into the 21st century.
VenomAid is a medtech company at the forefront of revolutionizing snakebite care on a global scale by pioneering affordable diagnostics to reach previously neglected populations.
+++++++++++++++++++++
////////////////////////////
Our resolve to bring about change was born from the urgency to bring snakebite care into the 21st century. Snakebite envenoming remains one of the world's most neglected tropical diseases, affecting millions annually and claiming over 100,000 lives.
By developing affordable technologies that can support clinical decision-making, we're committed to making snakebite care more accessible, efficient, and life-saving.
++++++++++++++++++++++++++++++
■
//////////////////////////////////////////////
positive result
blood sample
C
T
FLAGSHIP PROJECT
Rapid test for detection of
Bothrops atrox venom in clinical samples
Since our inception in 2018, we've been on a relentless pursuit of change. We're more than a biotech and medtech company; we're agents of transformation in the realm of snakebite care. Our core values are etched in every endeavor:
With simplicity, affordability, and reliability at the core of our diagnostic tests, we're rewriting the narrative of snakebite care, preserving limbs and lives.
Empowerment lies at the heart of our mission. We equip medical personnel across the globe with tools to improve snakebite management.
Neglected problems demand solutions. We're advocates for change, driving awareness about neglected tropical diseases and steering snakebite care to the forefront of global discourse.
Our team is an ensemble of scientists, entrepreneurs, and visionaries who have dedicated their careers to advancing the frontiers of snakebite envenoming research.
Jonas Arnold Jürgensen
Co-founder & CEO
Selma Belfakir
Industrial PhD student
Morten Munk
Board member
Jens Bøegh
Advisor
Cecilie Knudsen
Co-founder & CSO
Ana Paula Mendoza
Master's student
Mads Laustsen
Board member
Henrik Harboe
Advisor
Gina Ross
CTO
Gert Tomczyk
Chairman of the board
Chris Somerville
Board observer, Open Philanthropy
Jesper Kihl
Advisor
Pelle Knudsen
Research Scientist
Andreas Laustsen-Kiel
Co-founder and board member
Heather Youngs
Board observer, Open Philanthropy
2.7M
ENVENOMINGS
100T
DEATHS
400T
DISFIGUREMENTS
+5B$
LOST IN GDP$
We strive to advance the boundaries of science but also address critical knowledge gaps in the realm of snakebite envenoming.
Educational project together with LIFE foundation, titled FIGHT THE BITE
In Fight the Bite, students must investigate how antibodies can be used to both diagnose and treat snakebite envenomation.
Free course targeting htx and stx in the subject biology B in Denmark
Disposable materials for the course will be delivered at your high school
The duration of the course is three modules of 90 min.
AS FEATURED ON
.png){kind=logo}
Collaboration lies at the heart of our awareness endeavors. We forge partnerships with global health organizations, research institutions, manufacturers, and policymakers who share our commitment to alleviating the impact of snakebite envenoming. By aligning our efforts, we amplify our collective voice, advocate for increased funding for neglected tropical diseases, and influence policy decisions that catalyze change for snakebite victims globally.
GLOBAL ACCES DX
CENTER FOR ANTIBODY TECHNOLOGIES
FMT-HVD
